文献速递肾小球疾病

尿液蛋白质组生物标志物动态与IgA肾病疾病进展

Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本研究在活检确诊的IgA肾病患者中,于基线(IgAN237-1,n=103)和随访(IgAN237-2,n=89)时用毛细管电泳-质谱分析尿液,按IgAN237分类器(≤0.38为非进展者,>0.38为进展者)分组。结果显示IgAN237与eGFR斜率负相关,基线进展者是eGFR180天斜率的独立预测因子。结论认为IgAN237分类器可作为疾病动态过程中后期风险分层工具,可能指导个体化管理。

要点

  • IgAN237-1与IgAN237-2值无显著差异且相关(rho=0.44,P<.001)。
  • 进展者±180天eGFR斜率较非进展者更差(IgAN237-1中位-5.98 vs -1.22 mL/min/1.73 m2/年,P<.001)。
  • 基线IgAN237进展者/非进展者是eGFR180天斜率的独立预测因子(P=.001)。

核心结论

  • 尿液IgAN237分类器可作为IgA肾病动态病程后期风险分层工具,可能以个体化方式指导患者管理。

研究设计与样本

  • 对活检确诊的IgA肾病患者,在基线(IgAN237-1,n=103)和随访(IgAN237-2,n=89)时用毛细管电泳-质谱分析尿液,按IgAN237≤0.38和>0.38分为非进展者和进展者,计算eGFR和尿白蛋白-肌酐比值斜率。

主要发现

  • 活检时中位年龄44岁,活检至IgAN237-1间隔65个月,IgAN237-1至IgAN237-2间隔258天(四分位距71-531)。
  • IgAN237-1和IgAN237-2值无显著差异且相关(rho=0.44,P<.001)。
  • 基于IgAN237-1和IgAN237-2,分别有28%和26%的患者为进展者。
  • IgAN237与慢性eGFR斜率负相关(评分-1:rho=-0.278,P=.02;评分-2:rho=-0.409,P=.002),与±180天eGFR斜率负相关(rho=-0.31,P=.009;rho=-0.439,P=.001)。
  • 进展者±180天eGFR斜率较非进展者更差(IgAN237-1中位-5.98 vs -1.22 mL/min/1.73 m2/年,P<.001;IgAN237-2中位-3.02 vs 1.08 mL/min/1.73 m2/年,P=.0047)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunoglobulin A nephropathy (IgAN) frequently leads to kidney failure. The urinary proteomics-based classifier IgAN237 may predict disease progression at the time of kidney biopsy. We studied whether IgAN237 also predicts progression later in the course of IgAN. METHODS: Urine from patients with biopsy-proven IgAN was analyzed using capillary electrophoresis-mass spectrometry at baseline (IgAN237-1, n = 103) and at follow-up (IgAN237-2, n = 89). Patients were categorized as "non-progressors" (IgAN237 ≤0.38) and "progressors" (IgAN237 >0.38). Estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio slopes were calculated. RESULTS: Median age at biopsy was 44 years, interval between biopsy and IgAN237-1 was 65 months and interval between IgAN237-1 and IgAN237-2 was 258 days (interquartile range 71-531). IgAN237-1 and IgAN237-2 values did not differ significantly and were correlated (rho = 0.44, P < .001). Twenty-eight percent and 26% of patients were progressors based on IgAN237-1 and IgAN237-2, respectively. IgAN237 inversely correlated with chronic eGFR slopes (rho = -0.278, P = .02 for score-1; rho = -0.409, P = .002 for score-2) and with ±180 days eGFR slopes (rho = -0.31, P = .009 and rho = -0.439, P = .001, respectively). The ±180 days eGFR slopes were worse for progressors than for non-progressors (median -5.98 versus -1.22 mL/min/1.73 m2 per year for IgAN237-1, P < .001; -3.02 vs 1.08 mL/min/1.73 m2 per year for IgAN237-2, P = .0047). In multiple regression analysis baseline progressor/non-progressor according to IgAN237 was an independent predictor of eGFR180days-slope (P = .001). CONCLUSION: The urinary IgAN237 classifier represents a risk stratification tool in IgAN also later in the course of the dynamic disease. It may guide patient management in an individualized manner.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Peters B, Beige J, Siwy J, et al. Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy. Nephrol Dial Transplant. 2023. PMID: 37349951. doi:10.1093/ndt/gfad125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。